Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and reported. The objective of this review was to comprehensively characterize the incidence, presentation, and management of endocrinopathies following ipilimumab therapy in a single center that is highly specialized in immune checkpoint blockade. We carried out a retrospective analysis of endocrine irAEs in melanoma patients receiving ipilimumab therapy in clinical trials between 2007 and 2013. A total of 256 patients were included in this analysis. We reviewed pituitary-, thyroid-, and adrenal-related hormone test results, as well as radiographic studies and the clinical histories of patients, to identify and characterize cases of hypophysitis, hypothyroidism, thyroiditis, and adrenal dysfunction. Following ipilimumab therapy, the overall incidence of hypophysitis was 8% and that of hypothyroidism/thyroiditis 6%. Primary adrenal dysfunction was rare. Therapy with a combination of ipilimumab and nivolumab, an anti-programmed cell death 1 (PDCD1, also called PD1) receptor antibody, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis. Symptomatic relief, in particular, for hypophysitis, was achieved in all patients with hormone replacement, although endogenous hormone secretion rarely recovered. In summary, we observed that CTLA4 blockade alone, and in particular in combination with PD1 blockade, is associated with an increased risk of symptomatic, sometimes severe, hypophysitis as well as thyroid dysfunction. Prompt initiation with hormone replacement reverses symptoms. Evaluation and reporting of endocrine irAEs in clinical trials should be done using standardized diagnostic criteria and terminology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“novel biological drugs inducing hypophysitis such as ipilimumab or other check-point inhibitors (63).”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“the rexinoids (e.g. bexarotene), directly repressing TSHβ expression”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
In the citing paper
“mitotane, which decreases viability of thyrotrope cells”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The higher overall incidence of hypophysitis in the studies (8%) reviewed compared with that in most of the published trials probably reflects our welldefined clinical, biochemical, and radiographic criteria for identifying cases, which is highly inconsistent and ambiguous in published clinical trials (Hodi et al. 201…”
BackgroundResultInfluentialSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Nivolumab, a second antibody-derived immune regulator, blocks the activation of the anti-programmed cell death 1 (PDCD1, also called PD1) receptor (Topalian et al. 2012).”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 2×
“…pituitary hormone secretion. http://erc.endocrinology-journals.org q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0499 Printed in Great Britain There is a clear association betweenCTLA4 and sporadic, autoimmune thyroid disease in humans and mice (Tomer et al. 2001, Ueda et al. 2003).”
BackgroundInfluentialCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“The engagement of CTLA4 by its ligands in the B7 co-stimulatory family suppresses T-cell proliferation, helping restore tissue homeostasis (Egen et al. 2002, Pentcheva-Hoang et al. 2004).”
BackgroundCaturegli, P., Newschaffer, C., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 588
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Research works printed but not linked: 1
- 2005, 28, 593
Cited by
Items 301–400 of 460
A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab
Zhu, Y., Wu, H. H., & Wang, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194094 · Cited by 7
Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy
Velez, M. A., Kang, E., Thompson, C. A., Lind-Lebuffe, J. P., Shen, C., Park, S. J., Han, A., Gower, A., Li, D., Rochigneux, P., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00027 · Cited by 7
Thyroïdites : où en est-on en 2019 ?
Rouland, A., Buffier, P., Petit, J.-M., Vergès, B. L., & Bouillet, B. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.02.003 · Cited by 7
Li, Z., Liu, Z., Wei, H., Jin, S., Sun, Y., Zhang, Y., & Liu, Y. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.008 · Cited by 7
Brazel, D., Kazakova, V., Fay, M., Bollin, K. B., Mittal, K., Reynolds, K. L., & Tsang, M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473080 · Cited by 7
Diagnosis and Management of Neuroendocrine Disorders of Survivors of Brain Tumors
Erickson, D. Z., & Donegan, D. M. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321059 · Cited by 6
A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
Erra, A., Pannu, B. S., Patel, S., Qureshi, F. M., & Soliman, M. (2019) · Cureus · doi:10.7759/cureus.5001 · Cited by 6
Tang, Q., Han, Y., Song, M. C., Peng, J., Zhang, M., Ren, X., & Sun, H. (2024) · Medicine · doi:10.1097/md.0000000000037587 · Cited by 6
Albertelli, M., Rossi, G., Nazzari, E., Genova, C., Biello, F., Rijavec, E., Bello, M. G. D., Patti, L., Tagliamento, M., Barletta, G., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02268-0 · Cited by 6
Zhang, Y., Garofano, F., Wu, X., Schmid, M. C., Krawitz, P. M., Essler, M., & Schmidt‐Wolf, I. G. H. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00952-z · Cited by 6
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.12.001 · Cited by 6
Lesions in endocrine glands as a complication of immunotherapy in the practice of oncologist
Nuralieva, N. F., Troshina, E. A., & Mel'nichenko, G. A. (2019) · Clinical and experimental thyroidology · doi:10.14341/ket9875 · Cited by 6
Takagi, T., Yoshida, K., Kondo, T., Fukuda, H., Ishihara, H., Kobayashi, H., Iizuka, J., Ishida, H., & Tanabe, K. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab141 · Cited by 6
Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor
Sang, H., Cho, Y. K., Go, S.-H., Kim, H. J., & Koh, E. H. (2024) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.523 · Cited by 5
Thyroid Dysfunction from Treatments for Solid Organ Cancers
Kotwal, A., & McLeod, D. S. A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.006 · Cited by 5
Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
Inaba, H., Ariyasu, H., Okuhira, H., Yamamoto, Y., Akamatsu, H., Katsuda, M., Jinnin, M., Hara, I., & Akamizu, T. (2020) · Trends in Immunotherapy · doi:10.24294/ti.v4.i1.606 · Cited by 5
An Update on Immune Checkpoint Inhibitor-related Hypophysitis
Mortensen, M. J., Oatman, O. J., Azadi, A., Fonkem, E., & Yuen, K. C. J. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.117 · Cited by 5
Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro
Cosci, I., Toni, L. D., Fiore, P. D., Nisio, A. D., Carraro, S., Radu, C. M., Bertazza, L., Mocellin, S., Pigozzo, J., Crivellaro, G., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534975 · Cited by 5
Correction of endocrine complications of oncoimmunotherapy
Pigarova, E. A., Shutova, A. S., & Dzeranova, L. K. (2023) · Obesity and metabolism · doi:10.14341/omet12828 · Cited by 5
Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study
Poddubskaya, E. V., Sekacheva, M. I., & Guryanova, A. (2019) · Sechenov Medical Journal · doi:10.47093/22187332.2019.4.4-11 · Cited by 5
Higashiyama, R. I., Horinouchi, H., Kuchiba, A., Matsumoto, Y., Murakami, S., Goto, Y., Kanda, S., Fujiwara, Y., Yamamoto, N., & Ohe, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04205-9 · Cited by 5
Managing Immunotherapy-related Side Effects
Friedman, C. F., Postow, M. A., & Fellow (2015) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2015.11.02.143 · Cited by 5
Self-citationTănase-Damian, C., Antone, N. Z., Păun, D. L., Tanase, I. C., & Achimaș-Cădariu, P. (2026) · Diseases · doi:10.3390/diseases14020051 · Cited by 5
Yang, L., Zhang, Y., Chen, X., Liu, K., Zhou, Y., & Wang, S. (2024) · Clinical Endocrinology · doi:10.1111/cen.15075 · Cited by 4
George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.1.1.21 · Cited by 4
Hypophysitis Associated with Immune Checkpoint Inhibitors
Corsello, A., Paragliola, R. M., Torino, F., & Salvatori, R. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.06.009 · Cited by 4
Sheng, P., Guo, Y., Wu, Y., Xie, J., Wang, X., Wu, M., & An, X. (2026) · Medicine · doi:10.1097/md.0000000000048449 · Cited by 4
Geng, D., Wang, Y., Zhang, X., Zhao, C., Fan, Y., Liu, C. X., Wei, J., Huo, B., Zhao, Y., Zhang, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981084 · Cited by 4
Alqahtani, A. M., Alghamdi, L., Alghassab, A. S., & Almalki, M. (2023) · Cureus · doi:10.7759/cureus.44296 · Cited by 4
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
Hammerstad, S. S., Lee, H. J., Tomer, Y., & Stefan–Lifshitz, M. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02608-2 · Cited by 4
Fleseriu, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00012-x · Cited by 4
Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
Festino, L., & Ascierto, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_33 · Cited by 4
Tingry, T., Massy, E., Piperno, M., Auroux, M., Kostine, M., Maillet, D., Amini‐Adlé, M., Fabien, N., Estublier, C., Gonçalves, D., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.01.016 · Cited by 4
Park, H., Hata, A., Hatabu, H., Ricciuti, B., Awad, M. M., & Nishino, M. (2023) · Cancers · doi:10.3390/cancers15030649 · Cited by 4
Thyroiditis – A Clinical Update and Review
SINGER, P. A., Nguyen, C. N., & Nguyen, T. N. (2023) · doi:10.53901/tjbs.2023.08.art04 · Cited by 4
Jeung, H., Oh, S. E., & Kim, J. H. (2019) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2019.26.4.221 · Cited by 4
Cooksley, T., Higham, C., Lorigan, P. C., & Trainer, P. J. (2018) · Cancer · doi:10.1002/cncr.31789 · Cited by 4
Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer
Iglesias, P., Soria, A., & Díez, J. J. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.02.022 · Cited by 4
Kumar, A. B., Maus, R. L. G., & Markovic, S. N. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.03.028 · Cited by 4
T3 and T4 autoantibodies: emerging biomarkers for evaluating thyroid disorders
Liu, J., Mao, C., Mao, X., Wang, X., Zheng, T., Dong, L., & Mao, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1537222 · Cited by 3
Pembrolizumab-Induced Hypophysitis in the Setting of Renal Cell Carcinoma
Ogbodu, K., Sharda, M., Vanani, N. B., & Jha, P. (2025) · Cureus · doi:10.7759/cureus.82940 · Cited by 3
Souri, Z., & Pakdel, F. (2024) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v19i3.15047 · Cited by 3
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
Pavlick, A. C., & Weber, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_60 · Cited by 3
Onkodiabetológia III. Az antineoplasztikus terápiák és a szénhidrát-anyagcsere viszonya
Bánhegyi, R. J., Veréb, B., Gazdag, A., Rácz, B., Wagner, R. J., Fülöp, N., & Pikó, B. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32635 · Cited by 3
Zhang, X., Wu, Y., Lv, J., Li, X., Ma, L., Nong, J., Zhang, H., Qin, N., Zhang, Q., Shi, G., et al. (2019) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-019-00337-8 · Cited by 3
Immunothérapie et dysfonctions thyroïdiennes : mise au point sur les connaissances actuelles
Lambert, T., & Doucet, L. S. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2659-8 · Cited by 3
The Double-Edged Sword of Immunotherapy—Durvalumab-Induced Polyendocrinopathy—Case Report
Błażowska, O., Stróżna, K., Dancewicz, H., Zygmunciak, P., Zgliczyński, W., & Mrozikiewicz‐Rakowska, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216322 · Cited by 3
Management of Immunotherapy Related Adverse Effects
DeSouza, K., & Savva, C. (2016) · Journal of Cancer Prevention & Current Research · doi:10.15406/jcpcr.2016.06.00187 · Cited by 3
Neagu, M. T., & Constantin, C. (2015) · InTech eBooks · doi:10.5772/59494 · Cited by 3
Pituitary enlargement following ipilimumab without long term endocrine dysfunction
Nogueira, E. F., Menon, A., Dede, A. D., Mitra, I., Brock, C. S., Larkin, J., & Morganstein, D. L. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100710 · Cited by 3
Sammons, S. L., McNamara, M. A., Salama, A. K. S., & Crawford, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_12 · Cited by 2
TSH-Free Thyroxine Discordance in an Athyreotic Patient During Ipiluminab and Nivoluminab Therapy
Jonklaas, J. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15975.cr · Cited by 2
Toxicities of Novel Antineoplastic Therapies
Rajha, E., & Yeung, S. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_53 · Cited by 2
Tan, S., Wang, Y., Cai, Y., Guo, H., & Gao, Y. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2638068 · Cited by 2
Almutairi, A. R., Erstad, B. L., McBride, A., Slack, M. K., & Abraham, I. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1877272 · Cited by 2
Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer
Lin, M., Bai, L., Yeh, S.-P., Chiu, C., & Lien, M.-Y. (2024) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-23-00025 · Cited by 2
The Long-Term Endocrine Sequelae of Multimodality Cancer Therapy
Murray, R. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00042-3 · Cited by 2
Chida, T., Matsuda, A., Maishi, N., Nakajima, K., Sato, M., Zi, J., Ohiro, Y., Ogawa, M., Hida, Y., & Hida, K. (2025) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2025.01.006 · Cited by 2
Verelst, F. R., Beyens, M. M. J., Vandenbroucke, E., Forceville, K., & Twickler, M. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13790 · Cited by 2
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
Riveiro‐Barciela, M., Araguás, E. T., Martínez‐Valle, F., Roca-Herrera, M., Zamora, E., Barreira‐Díaz, A., & Muñoz‐Couselo, E. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.06.030 · Cited by 2
Zherebchikova, K., Sych, Y. P., Amosova, M., Sekacheva, M. I., Fadeev, V. V., & Vilenskiy, A. A. (2022) · Russian Medical Inquiry · doi:10.32364/2587-6821-2022-6-9-528-533 · Cited by 2
L’hypophysite auto-immune, complication des nouvelles immunothérapies anticancéreuses
Jannin, A., Merlen, E., Cao, C. D., & Penel, N. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.10.033 · Cited by 2
Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer
Kajal, S., Gupta, P., Ahmed, A., & Gupta, A. K. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01006 · Cited by 2
Endokrine Nebenwirkungen onkologischer Immuntherapien
Kroiß, M., Schilling, B., & Deutschbein, T. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1140-2920 · Cited by 2
Evens, A., Cyriac, G., Jeong, D. K., Araujo, C., Gage, K. L., & Rose, T. A. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.02.008 · Cited by 2
Management of Melanoma Therapy-Associated Toxicities
Weiss, S. A., Kavecansky, J., & Pavlick, A. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803508-5.00020-2 · Cited by 2
Shapiro, M., Dor, H., Gurevich‐Shapiro, A., Etan, T., & de Wolf, I. (2024) · arXiv (Cornell University) · doi:10.48550/arxiv.2403.09708 · Cited by 2
Diagnosis and Management of Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
Fazer-Posorske, C., Kottschade, L. A., & Schwecke, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_14 · Cited by 2
Nonpituitary Sellar Masses and Infiltrative Disorders
Mehta, S., Cohen, B., & Kohn, B. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11339-1_10 · Cited by 2
Progress in Research on Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) and Bladder Cancer
Fang, W.-M., & Chen, C. (2019) · annals of urologic oncology · doi:10.32948/auo.2019.01.22 · Cited by 2
Osman, H., Sanjeevi, A., & Hsu, C.-Y. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-266771 · Cited by 2
Liu, W., Wang, L., Song, X., Ye, X., Ding, Y., Liu, J., & Du, Q. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05363-0 · Cited by 2
Anti-cancer therapy-induced metabolic syndrome
Řiháčková, E., Elbl, L., Říháček, M., Holická, M., & Kala, P. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.089 · Cited by 2
Cancer immunotherapy associated hypophysitis: Pathophysiology and management
Das, S. K., & Sen, K. (2022) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2022.15.2.0819 · Cited by 1
Colombo, C., Leo, S. D., Campisi, I., Palesandro, E., Turco, F., Buttigliero, C., Fugazzola, L., & Tucci, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104627 · Cited by 1
Xiang, M., Liu, S., Xiao, D., & Tao, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02810-5 · Cited by 1
Angell, T. E., Kim, M. I., & Bernet, V. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-66127-0.00004-1 · Cited by 1
Endocrinopatias secundárias ao uso de inibidores de checkpoints imunológicos
de Castro, M. J., Veríssimo, D., Marcelino, M., & de Castro, J. J. (2021) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/cc190063 · Cited by 1
Endocrine Toxicities of Immunotherapy
Pandey, M. R., Goyal, I., & Ernstoff, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00018-5 · Cited by 1
Sawaf, M. (2018) · theses.fr (ABES) · doi:10.70675/eaf792a1zb140z4edcz9257ze075f23bca45 · Cited by 1
Immune-modulating medications: the masquerading culprit of epididymo-orchitis
Buchinsky, D. S., Polenakovik, H. M., & Hakim, J. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-267699 · Cited by 1
Hasan, M., Samlowski, W. E., & Nakhle, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1827644 · Cited by 1
Overview and management of toxicities of immune checkpoint-blocking drugs
Economopoulou, P., & Psyrri, A. K. (2016) · Forum of Clinical Oncology · doi:10.1515/fco-2016-0004 · Cited by 1
Wémeau, J.-L., BERTAGNA, X. Y., & Boîtard, C. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30188-8 · Cited by 1
Differential diagnosis of pituitary enlargement
Štěchovská, K., Tůma, T., Masopust, V., & Kosák, M. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.008 · Cited by 1
Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review
Buch, S. A., & Baba, M. R. (2022) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0042-1742442 · Cited by 1
Immune-Related Adverse Toxicities and Clinical Management
Kirchberger, M. C., & Heinzerling, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_36 · Cited by 1
Management and Supportive Care of Patients Undergoing Immunotherapy
Rapoport, B. L., & Eeden, R. I. V. (2017) · InTech eBooks · doi:10.5772/67372 · Cited by 1
Sehgal, V., & Childress, R. D. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0039 · Cited by 1
Anti-CTLA-4 Monoclonal Antibodies Induced Hypophysitis: Case Report and Literature Review
Jaafar, J., & Philippé, J. (2017) · Annals of Clinical Case Reports · Cited by 1
Kottschade, L. A., & Yan, Y. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00649 · Cited by 1
Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
Kottschade, L. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70622-1_9 · Cited by 1
64-Year-Old Man With Altered Mental Status
Schmidt, T. J., Subat, Y. W., & de Moraes, A. G. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.12.034 · Cited by 1
Hershman, J. M. (2015) · Clinical Thyroidology · doi:10.1089/ct.2015;27.185-186 · Cited by 1
(2018) · The Medicine Forum · doi:10.29046/tmf.019.1
Aspects of hypogonadism in oncological patients receiving antitumor treatment. Literature review
Abramov, M. Е., Israelyan, E. R., Tsareva, А. S., Rumyantsev, А. А., Firsov, K. A., & Matveev, V. B. (2025) · Cancer Urology · doi:10.17650/1726-9776-2025-21-1-119-125
Cancer immunotherapy-associated endocrine complications and treatment strategies
Sen, K., Adhikari, M., Biswas, C., Maity, S., Chatterjee, A., & Pramanick, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00010-8
Cancer Immunotherapy Related Endocrine Adverse Effects
Kim, H., Cho, S. W., & Park, Y. J. (2019) · International Journal of Thyroidology · doi:10.11106/ijt.2019.12.2.97
Endocrinopathies Associated With Immune Checkpoint Inhibitors
Girotra, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00024-7
Zhou, C., & Luo, P. (2022) · PanCancer · doi:10.58510/xdqx2766
Metadata
- Authors
- Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A.
- Affiliations
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Ryder, Mabel
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-04
- Volume
- 21
- Issue
- 2
- Pages
- 371-381
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- PMC
- PMC4573438
- OpenAlex
- W2166107256
- Cited by
- 439
- References
- 14
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 32 · 2021: 44 · 2020: 49 · 2019: 55 · 2018: 53 · 2017: 56 · 2016: 44 · 2015: 25 · 2014: 5
- FWCI
- 20.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- National Cancer Institute (K08CA133183, P50CA172012, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- ipilimumab, immune-related adverse events, CTLA-4 blockade, immune checkpoint inhibitors, advanced melanoma, hypophysitis, hypothyroidism, thyroiditis, adrenal dysfunction, nivolumab, anti-PD-1 therapy, hormone replacement therapy, endocrine toxicity
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Endocrine System Diseases, Humans, Melanoma, Skin Neoplasms, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.